ScreenerHero

CORT Corcept Therapeutics Incorporated

NAS · US · Healthcare · Biotechnology · corcept.com
122.03USD+4.99%Mkt Cap: 13.19B $P/E: 271.18

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap13.19B USD
Enterprise Value12.27B USD
Revenue (TTM)830.81M USD
Gross Profit748.43M USD
Net Income (TTM)99.65M USD
Revenue/Share7.97 USD
Last Price122.03 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees730
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)271.18
P/E (Forward)26.40
PEG0.81
EV/EBITDA1517.26
EV/Revenue14.76
P/S15.12
P/B17.77
EPS (TTM)0.45
EPS (Forward)4.40
52W Range
28.6698% of range124.01
52W High124.01 USD
52W Low28.66 USD
Profitability
Gross Margin98.30%
Oper. Margin16.12%
EBITDA Margin0.97%
Profit Margin13.09%
ROE15.38%
ROA11.91%
Growth
Revenue Growth31.70%
Earnings Growth24.10%
Cash Flow & Leverage
Operating CF142.00M USD
CapEx (TTM)211.00K USD
FCF Margin9.32%
FCF Yield0.59%
Net Debt-298.78M USD
Net Debt/EBITDA-36.96
Balance Sheet
Debt/Equity0.01
Current Ratio2.86
Quick Ratio2.50
Book Value/Sh6.54 USD
Cash/Share2.85 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)141.00 USD
Upside (mean)+15.5%
Target Range50.00 USD – 165.00 USD
50.00+15.5% to mean165.00
# Analysts5
Ownership
Shares Out.108.10M
Float96.48M
Insiders11.45%
Institutions76.88%
Short Interest
Short Ratio10.7d
Short % Float11.14%
Short % Out.8.65%
Shares Short9.35M
Short (prev mo.)9.70M
Technical
SMA 50113.00 (+8.0%)
SMA 20069.92 (+74.5%)
Beta0.45
S&P 52W Chg14.58%
Avg Vol (30d)1.41M
Avg Vol (10d)961.43K
Technical Indicators
RSI (14)62.7
MACD2.0130
MACD Signal1.9554
MACD Hist.+0.0576
BB Upper120.06 USD
BB Middle114.62 USD
BB Lower109.18 USD
BB Width9.49%
ATR (14)5.358 USD
Vol Ratio (20d)0.59x